Which of the following medications is NOT associated with type II diabetes treatment?

In the context of diabetes treatment, Insulin Glargine is primarily used for managing blood glucose levels in individuals with type I diabetes and those with advanced type II diabetes who require insulin for optimal glucose control. While it is a critical component of the overall management of diabetes, it is not specifically recognized as an oral hypoglycemic agent typically used in the initial treatment of type II diabetes. Instead, medications like Repaglinide, Metformin, and Sitagliptin are specifically designed to enhance insulin sensitivity, stimulate insulin secretion, or improve glycemic control without requiring the use of injectable insulin.

Repaglinide is a meglitinide that stimulates the pancreas to release more insulin in response to meals. Metformin works primarily by decreasing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. Sitagliptin is a DPP-4 inhibitor that helps to increase incretin levels, leading to enhanced insulin secretion and reduced glucagon levels when glucose is elevated. These mechanisms direct focus on managing type II diabetes without necessitating the use of insulin for every patient, which differentiates them from Insulin Glargine.